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Abstract
Tumor lysis syndrome is a potentially lethal complication of chemotherapy, usually associated
with aggressive hematologic malignancies. We describe the case of a young patient with metastatic hepatocellular cancer who developed rapid and fatal tumor lysis syndrome following initiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular
carcinoma, tumor lysis syndrome is serious complication. Patients with a high burden of disease
at therapy initiation should have their metabolic parameters measured prior to starting therapy
and closely followed for the first 1–2 weeks while being treated.
Ó 2018 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
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Tumor lysis syndrome (TLS) is a serious and potentially
lethal complication of chemotherapy that ensues following
rapid necrosis of malignant cells [1], often with underlying
heavy disease burden. It is most commonly associated with
chemotherapy administered for rapidly proliferating hematologic malignancies like acute leukemia or high grade
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lymphomas. It is unusual for TLS to occur with hepatocellular cancer (HCC) following treatment with sorafenib, an oral
tyrosine kinase inhibitor, which is the only drug approved
for use in metastatic HCC [2]. Only seven cases of
sorafenib-associated TLS have been reported in literature
to date [3–9]. We review the relevant literature and
describe the case of a patient with metastatic HCC who
developed fatal TLS within seven days of initiation of
sorefnib.

Case summary
49 year old man was admitted to the hospital via the emergency department after he presented with abdominal swelling, decreased appetite, nausea, weight loss and lower
extremity edema. He was noted to have microcytic anemia
(hemoglobin 7.5 g/dL; MCV 65 fL), platelets of 308  109/L,
INR of 1.1, alkaline phosphatase of 288 U/L, total bilirubin
of 1.72 mg/dL and albumin 3.8 g/dL. Additional laboratory
values are listed in Table 1.
A computed tomography (CT) scan of the chest, abdomen
and pelvis showed an enlarged liver with innumerable
masses (largest 11.3  10.1 cm), 2.3 cm portacaval lymphadenopathy, 2.4 cm left adrenal nodule and multiple
sub-centimeter mediastinal lymph nodes. Alpha fetoprotein
was 70,753 ng/mL. He was categorized into the Child Class
A (Child-Pugh score = 6) and an ultrasound guided biopsy
of the largest hepatic mass was confirmatory for well differentiated HCC.
On day 0, he was started on palliative therapy with sorafenib, 200 mg twice daily. He was seen in clinic for follow
up on day 7 and was noted to several metabolic abnormalities suggestive of tumor lysis syndrome as summarized in
Table 1.
The patient was admitted to the hospital and given
rasburicase, 10 mg intravenously. The nephrology service
was involved and he also received furosemide, sodium
polystyrene sulfonate and midodrine. Unfortunately, he
continued to get progressively oliguric and acidotic,
developing severe anasarca with associated hypoxia. He
elected not to proceed with intubation, declined dialysis
and left the hospital against medical advice on day 6.
He was brought back to the emergency room on day 14,
when he suffered a cardiopulmonary arrest and unfortunately passed away.

Table 1
14.

Discussion
TLS is characterized by development of acute kidney injury
and other metabolic abnormalities including hyperuricemia,
hyperkalemia, hypocalcemia and hyperphosphatemia after
exposure to chemotherapy [1]. These derangements arise
from rapid breakdown of neoplastic cells with release of
intracellular contents into the circulation which can then
exert deleterious effects on the kidneys and other organ
systems which complicates treatment course. It is most frequently encountered in the initial treatment of aggressive
and, notably, chemo- and radio-sensitive, hematologic
malignancies. It is less common in solid tumors, which have
a relatively lower proliferative index and treatment
sensitivity.
Advanced (metastatic or multinodular) HCC is currently
treated with sorafenib, which works by inhibiting serinethreonine kinases, as well as tyrosine kinases associated
with vascular endothelial growth factor receptors (VEGFRs) 1,2,3 and platelet-derived growth factor receptor b
(PDGFR-b) [2]. In the seminal SHARP trial [2], sorafenib
monotherapy for advanced HCC demonstrated an improved
overall survival compared to best supportive care alone. No
complete responses were seen, while partial response was
noted in only 2% of the patients. 71% of patients had stable
disease which was in part due to tumor necrosis without a
change in size meeting criteria for response.
Based on the usually slow-growing nature of HCC (in comparison to hematologic malignancies), and the low response
rates and mechanism of action of sorafenib, most clinicians
do not expect to encounter TLS when sorafenib therapy is
initiated. To the best of our knowledge, there are only
seven previous reports of sorafenib-induced TLS in HCC
patients reported in literature [3–9]. Most of these reports
are from far-east Asia with one from the US and none from
Europe or Africa. It is difficult to say whether this geographic difference is due to different underlying disease
biology in the far-east-Asian population (including the
greater prevalence of viral hepatitis), or simply due to different levels of interest in reporting and publishing. A
detailed comparison of the seven published cases is presented in Table 2.
As can be noted, all cases had a relatively high disease
burden, with either frank metastatic disease, or multiple
nodules in the liver. In some cases, prior local therapy to

Laboratory values at the time of sorafenib initiation, discontinuation of therapy on day 7 and demise of patient at day

Laboratory parameter

Day 0 (initiation)

Day 7 (admission)

Day 14 (demise)

Serum potassium (mEq/L)
Serum creatinine (mg/dL)
Serum uric acid (mg/dL)
Alanine transaminase (U/L)
Aspartate transaminase (U/L)
Total bilirubin (mg/dL)
Lactate dehydrogenase (U/L)
Serum calcium (mg/dL)
Serum phosphorus (mg/dL)

3.8
0.7
10.3
84
166
1.72
815
8.6
Not checked

5.37
2
>20
49
291
2.98
2096
8.8
5.2

7.8
5.3
3.2 (s/p rasburicase)
515
3424
2.4
20,779
7.5
18.9
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Reported cases of tumor lysis syndrome in patients with hepatocellular carcinoma treated with sorafenib [2–9].

Author (year)
[reference]

HCC stage at the start of
sorafenib therapy (AFP)

Other relevant characteristics

Days from sorafenib
therapy to
development
of TLS

Final outcome
of TLS

Kim et al. [3]

Metastatic (1795 mg/L)

Hepatitis B Tumor thrombus in
LHV, IVC & RA

8

Kudo et al. [4]
Habib et al. [5]

Multifocal (11 ng/mL)
Metastatic (>1500 IU/mL)

7
21

Abbass et al. [6]
Joshita et al. [7]
Shiozawa et al. [8]
Huang et al. [9]

Unresectable
Metastatic (2580 ng/mL)
Multifocal
Multifocal (9828 mg/L)

Fever and anorexia at day 5
Hepatitis B Had liver transplant
History of PE
Hepatitis B Alcoholism
Previous TACE
Hepatitis C
Child score 8 Hepatitis B
PV thrombus

Declined HD;
Transferred to
nursing home
Mild CKD
Fatal

7
7
10
30

Declined HD Fatal
Recovered
Recovery
Fatal

AFP; alpha-fetoprotein, CKD; chronic kidney disease, HCC; hepatocellular carcinoma, HD; hemodialysis, IVC; inferior vena cava, LHV; left
hepatic vein, PE; pulmonary embolism, PV; portal vein, RA; right atrium, TACE; transarterial chemoembolization, TLS; tumor lysis
syndrome.

the liver nodules had already been attempted. Furthermore, four out of the seven cases had underlying hepatitis
B [3,5,6,9], while one had hepatitis C [8]. The time of onset
of TLS ranged from 7 days to 30 days while 3 out of the 7
cases were fatal, as was the case with our patient. Good
outcomes were noted when TLS was detected early, sorafenib was discontinued at the earliest suspicion of TLS and
aggressive supportive care was initiated early in the course
[4,7,8]. This corroborates that early detection and intervention are paramount in preventing more serious sequelae.
TLS in the present case was also detected early, and the
outcome could have potentially been non-fatal. Unfortunately, the patient left the hospital against medical advice
before supportive and interventions, including hemodialysis, could be started.
It is also interesting to note that our patient developed
TLS despite the fact that we had begun treatment with a
50% dose reduction from the standard 400 mg daily dose.
Notably, our patient had a slightly elevated serum uric acid
level prior to initiation of therapy. It is conceivable that he
was already in a state of spontaneous tumor lysis even
before therapy, but that may be less likely given the rarity
of spontaneous TLS in solid tumors [10].
To conclude, although rare, TLS is a potential complication during sorafenib treatment for advanced HCC with
heavy disease burden. The time of onset is usually within
the first 1–3 weeks. Early recognition, drug discontinuation
and aggressive supportive measures are crucial for a favorable outcome. Patients with a high burden of disease at
therapy initiation should have their metabolic parameters
prior to therapy and closely followed for the first 1–2
weeks. Prospective studies may lead to further insights into
TLS after sorafenib therapy and development of risk stratification methods to institute preemptive therapy to improve
patient outcomes.
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